Insomnia Drugs: What Causes It and What Treats It

How Common Is Insomnia and Why Does It Matter?

Insomnia is the most prevalent sleep disorder in the world. Estimates from epidemiological surveys place short-term insomnia in roughly 30% of adults at any given time, while chronic insomnia disorder, defined by the International Classification of Sleep Disorders Third Edition (ICSD-3) as difficulty initiating or maintaining sleep at least three nights per week for three or more months, affects 6 to 10% of the general population. [1]

The downstream consequences extend well beyond fatigue. A 2016 meta-analysis published in Sleep Medicine Reviews found that people with insomnia disorder had a 45% higher risk of cardiovascular disease compared with normal sleepers. Occupational impairment, increased healthcare utilization, and a 2- to 3-fold elevated risk of major depressive disorder are also consistently documented. [2]

Why Clinicians Often Miss Drug-Induced Insomnia

Drug-induced insomnia is frequently underdiagnosed because symptom onset may be delayed by days or weeks after starting a new medication. Many patients and even some prescribers attribute poor sleep to stress or aging rather than reviewing the medication list. A careful medication reconciliation is therefore one of the first steps in any insomnia workup.

The Bidirectional Drug-Sleep Relationship

Medications can both cause and treat insomnia. That bidirectional relationship makes the history-taking specific: the clinician needs to know not only what a patient takes, but when they take it, at what dose, and for how long.

Drugs That Commonly Cause Insomnia

Several widely prescribed drug classes disrupt sleep architecture, delay sleep onset, or reduce total sleep time. Recognizing them is a critical step before adding a sedative-hypnotic to the regimen.

Stimulants and ADHD Medications

Amphetamine salts (Adderall) and methylphenidate increase central norepinephrine and dopamine, directly prolonging sleep-onset latency. A 2017 review in CNS Drugs reported that 30 to 40% of adults on stimulant therapy for ADHD describe clinically significant insomnia. [3] Timing the dose earlier in the day (before noon for long-acting formulations) reduces but does not eliminate this effect. Lisdexamfetamine shows a similar profile.

Corticosteroids

Prednisone, dexamethasone, and methylprednisolone are among the most potent drug-induced insomnia triggers. Doses above 20 mg prednisone-equivalent per day produce sleep disruption in the majority of patients through HPA-axis activation and direct arousal effects on the locus coeruleus. Clinicians should consider morning dosing and the shortest effective course. [4]

Antidepressants

The relationship between antidepressants and sleep is complicated. Activating antidepressants, specifically fluoxetine (Prozac), venlafaxine (Effexor), and bupropion (Wellbutrin), increase REM suppression and nocturnal arousal. The STAR*D trial documented insomnia as a treatment-emergent adverse event in approximately 20% of patients on citalopram, which is considered a relatively sedating SSRI. [5] Mirtazapine and trazodone, by contrast, are sedating and are sometimes added specifically to treat antidepressant-induced insomnia.

Beta-Blockers

Atenolol, metoprolol, and propranolol suppress melatonin synthesis by blocking beta-1 adrenergic receptors in the pineal gland. Propranolol also crosses the blood-brain barrier and produces nightmares and sleep fragmentation as a direct CNS effect. Switching to a hydrophilic beta-blocker such as atenolol can reduce but may not eliminate this effect.

Decongestants and Bronchodilators

Pseudoephedrine, phenylephrine, and the short-acting beta-2 agonist albuterol produce adrenergic stimulation that delays sleep onset. Patients with allergic rhinitis or asthma are therefore at elevated risk for insomnia that is actually iatrogenic. [6]

Other Notable Culprits

• Thyroid hormone (levothyroxine): Doses that cause even subclinical hyperthyroidism accelerate heart rate and increase arousal.
• Diuretics: Nocturia from evening doses of furosemide or hydrochlorothiazide fragments sleep mechanically rather than neurochemically.
• Fluoroquinolones (ciprofloxacin, levofloxacin): GABA-A antagonism at high systemic concentrations is the proposed mechanism for reported insomnia and anxiety.
• Nicotine replacement therapy: Nicotine patches worn overnight increase REM suppression and produce vivid dreams in a subset of users.

First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I is not a soft alternative to medication. Every major guideline, including the American Academy of Sleep Medicine (AASM) 2021 Clinical Practice Guidelines, designates CBT-I as the first-line treatment for chronic insomnia disorder in adults. [7]

What CBT-I Actually Involves

CBT-I is a structured, multicomponent intervention typically delivered over 6 to 8 weekly sessions. The core components are:

• Sleep restriction therapy: Limiting time in bed to match actual sleep time, then extending it as efficiency improves.
• Stimulus control: Reserving the bed for sleep and sex only, eliminating reading, screens, and wakefulness in bed.
• Sleep hygiene education: Standardizing wake times, managing caffeine and alcohol, and optimizing the sleep environment.
• Cognitive restructuring: Identifying and challenging catastrophic thoughts about sleep loss.
• Relaxation techniques: Progressive muscle relaxation, diaphragmatic breathing.

Evidence Base for CBT-I

The evidence for CBT-I is substantial. A Cochrane review (Trauer et al., 2015, N=1,162 across 20 trials) found that CBT-I produced a mean reduction in sleep-onset latency of 19.03 minutes (95% CI 14.12 to 23.93) and wake-after-sleep-onset reduction of 26.00 minutes (95% CI 15.48 to 36.52) compared with control conditions. [8] These gains are durable at 12-month follow-up, unlike those from pharmacotherapy, which tend to regress after discontinuation.

Digital CBT-I (Sleepio, Somryst) shows comparable efficacy to therapist-delivered CBT-I for mild-to-moderate insomnia, increasing access for patients who cannot find a trained sleep psychologist.

FDA-Approved Pharmacotherapy for Insomnia

When CBT-I produces inadequate response after 6 to 8 weeks, or when insomnia is severe enough to warrant faster symptom relief, pharmacotherapy is appropriate as an adjunct. Drug selection depends on the insomnia subtype (sleep-onset, sleep-maintenance, or mixed), comorbidities, and patient age.

Dual Orexin Receptor Antagonists (DORAs)

Suvorexant (Belsomra) and lemborexant (Dayvigo) block orexin-A and orexin-B signaling at OX1R and OX2R receptors, reducing the wake-drive rather than sedating the patient directly. This mechanism is considered to produce a more naturalistic sleep with less residual sedation.

The SUNRISE-1 trial (N=1,023) demonstrated that suvorexant 20 mg significantly improved subjective sleep-onset latency (sSO) and wake-after-sleep-onset (sWASO) vs. Placebo at weeks 1 and 3, with a favorable next-morning alertness profile. [9] Suvorexant is available in 5, 10, 15, and 20 mg doses; the maximum recommended dose in most adults is 20 mg taken within 30 minutes of bedtime.

Lemborexant (Dayvigo 5 mg or 10 mg) showed superiority to placebo and non-inferiority to zolpidem tartrate extended-release for sleep-onset and sleep-maintenance outcomes in the SUNRISE-2 trial (N=949, 12-month duration). [10]

Low-Dose Doxepin (Silenor)

Doxepin 3 mg and 6 mg (Silenor) are the only FDA-approved doses specifically indicated for sleep-maintenance insomnia. At these doses, the mechanism is primarily histamine H1 receptor antagonism with minimal anticholinergic burden. A Phase 3 trial (N=221) confirmed that doxepin 6 mg significantly improved sleep maintenance relative to placebo without causing next-day sedation or rebound insomnia upon discontinuation. [11]

Z-Drugs: Zolpidem, Eszopiclone, and Zaleplon

Zolpidem (Ambien) acts as a positive allosteric modulator at GABA-A receptors containing alpha-1 subunits, producing rapid sleep onset. The FDA mandated lower recommended doses in 2013: 5 mg (women) and 5 to 10 mg (men) for immediate-release; 6.25 mg (women) and 6.25 to 12.5 mg (men) for extended-release. This change came after post-marketing data showed that 10 mg doses produced next-morning blood levels above the threshold for impaired driving in a significant minority of women. [12]

Eszopiclone (Lunesta) has FDA approval for both sleep-onset and sleep-maintenance insomnia with no restriction on duration of use, unlike older benzodiazepine approvals. Zaleplon (Sonata) has a half-life of approximately 1 hour, making it suitable for middle-of-the-night awakenings when at least 4 hours remain before the required wake time.

Boxed Warning: The FDA issued a Boxed Warning for all Z-drugs in 2019, noting rare but serious complex sleep behaviors including sleepwalking, sleep-driving, and sleep-related eating that have resulted in injuries and deaths. [12]

Benzodiazepines

Temazepam (Restoril), triazolam (Halcion), and estazolam are FDA-approved for insomnia but are generally relegated to second- or third-line use given dependence potential, residual sedation, and fall risk in older adults. The American Geriatrics Society Beers Criteria explicitly lists all benzodiazepines as medications to avoid in adults over 65 years old for this indication. [13]

Ramelteon (Rozerem)

Ramelteon is a melatonin MT1/MT2 receptor agonist approved for sleep-onset insomnia. It carries no abuse potential, no dependency signal, and no next-day cognitive impairment in clinical trials. Its effect size on sleep-onset latency is modest (approximately 7 to 8 minutes vs. Placebo) but it can be useful in patients where sedative-hypnotics are contraindicated, including those with a history of substance use disorder. [14]

Over-the-Counter Sleep Aids

Melatonin

Melatonin is the most commonly used OTC sleep aid in the United States. Meta-analytic data (Ferracioli-Oda et al., 2013, N=1,683 across 19 trials) found a mean sleep-onset reduction of 7.06 minutes (95% CI 4.37 to 9.75) and modest improvements in total sleep time. [15] The evidence is strongest for circadian-rhythm disruptions such as jet lag and shift-work insomnia. Doses of 0.5 to 1 mg taken 30 to 60 minutes before bed are physiologically replicated; higher doses (5 to 10 mg) commonly sold in the US produce supraphysiologic serum levels without proportionally greater benefit.

Antihistamines (Diphenhydramine and Doxylamine)

Diphenhydramine (Benadryl, ZzzQuil) and doxylamine (Unisom) produce sedation through H1 receptor blockade. Tolerance develops within 3 to 4 days of regular use. Both agents are listed on the Beers Criteria for older adults due to anticholinergic effects including cognitive impairment, urinary retention, and constipation. [13] They are appropriate only for occasional, short-term use in adults under 60 who have no prostatic or cognitive vulnerabilities.

Special Populations and Drug Selection

Insomnia in Older Adults

Pharmacokinetic changes in aging, including reduced hepatic clearance and increased CNS sensitivity, make drug selection more cautious in adults over 65. Low-dose doxepin 3 mg and ramelteon are preferred pharmacologic options. Suvorexant at 10 mg (not 20 mg) is also considered reasonable. CBT-I remains first-line regardless of age, and digital delivery formats may be accessible even for homebound older adults. [7]

Insomnia in Pregnancy

CBT-I is the preferred and safest treatment. No pharmacologic sleep aid has a well-established safety record in pregnancy. Doxylamine is classified as Pregnancy Category A in some international regulatory frameworks and is FDA-approved in combination with pyridoxine for nausea (Diclegis/Bonjesta), but its use as a sleep aid in pregnancy is off-label and should be approached cautiously with shared decision-making. Benzodiazepines and Z-drugs are generally avoided given risks of neonatal withdrawal and respiratory depression. [16]

Insomnia with Comorbid Depression or Anxiety

Trazodone is one of the most commonly prescribed medications for insomnia in the United States despite lacking an FDA indication for this use. Its sedating properties stem from histamine H1 and alpha-1 adrenergic blockade. At doses of 25 to 100 mg at bedtime, it may address both mood and sleep symptoms in patients with comorbid depression. However, a 2018 randomized trial by Roth et al. (N=306) found trazodone 50 to 100 mg inferior to eszopiclone for sleep-maintenance outcomes at 8 weeks. [17]

Diagnosing Insomnia: Clinical Criteria and Tools

ICSD-3 and DSM-5 Criteria

The ICSD-3 defines chronic insomnia disorder as self-reported difficulty with sleep initiation, maintenance, or early-morning awakening, occurring at least 3 nights per week for at least 3 months, causing significant distress or daytime impairment, and not adequately explained by another sleep disorder or substance. DSM-5 uses nearly identical criteria.

Validated Screening Tools

• Insomnia Severity Index (ISI): A 7-item self-report scale; scores of 15 to 21 indicate moderate insomnia, 22 to 28 indicate severe insomnia.
• Pittsburgh Sleep Quality Index (PSQI): A 19-item instrument covering 7 components of sleep quality over the prior month.
• Epworth Sleepiness Scale (ESS): Useful to distinguish insomnia from disorders of excessive daytime sleepiness such as obstructive sleep apnea or narcolepsy, which require different management.

When Polysomnography Is Needed

Routine polysomnography is not recommended for diagnosing insomnia. The AASM specifies that polysomnography is indicated when a comorbid sleep disorder such as obstructive sleep apnea, periodic limb movement disorder, or REM sleep behavior disorder is suspected based on history or when insomnia fails to respond to adequate CBT-I and pharmacotherapy trials. [7]

When to Worry: Red Flags That Warrant Urgent Evaluation

Most insomnia is chronic-course and not a medical emergency. The following features should prompt expedited evaluation rather than empirical sleep-aid prescribing:

• Loud snoring, witnessed apneas, or excessive daytime sleepiness: These suggest obstructive sleep apnea, which worsens with sedative-hypnotics.
• Abnormal movements during sleep or acting out dreams: REM sleep behavior disorder, which is an early marker of alpha-synucleinopathy (Parkinson's disease, Lewy body dementia) in 80 to 90% of cases at 12-year follow-up.
• Insomnia onset after a new medication: Review the medication list before adding a sleep aid.
• Insomnia with prominent nightmares and hyperarousal in a trauma survivor: Screen for PTSD; prazosin 1 to 15 mg at bedtime has trial evidence for nightmare reduction in PTSD.
• Insomnia with mood symptoms, weight change, or cognitive decline: Rule out major depressive disorder, hypothyroidism, or early dementia before attributing symptoms to primary insomnia.

The HealthRX clinical team applies a three-step triage framework for new insomnia presentations: (1) medication reconciliation to identify and address drug-induced insomnia first; (2) screening for comorbid sleep, psychiatric, or medical disorders that require targeted treatment; and (3) initiating CBT-I before any pharmacotherapy is prescribed, reserving drug selection for patients with incomplete CBT-I response or who require faster relief while CBT-I takes effect.

Drug Interactions That Worsen Insomnia or Amplify Sedative Risks

Combining sedative-hypnotics with other CNS depressants multiplies the risk of respiratory depression, over-sedation, and complex behaviors. The FDA issued a Drug Safety Communication in 2016 specifically warning against co-prescribing benzodiazepines or Z-drugs with opioids, noting that 30% of opioid overdose deaths involved a concurrent benzodiazepine. [18]

Alcohol deserves specific mention. A single serving of alcohol may reduce sleep-onset latency but fragments sleep in the second half of the night through rebound REM activation and increases total wake time. Patients using any sedative-hypnotic should be counseled to avoid alcohol completely, not simply to "drink less."

Caffeine's adenosine-antagonism effect persists for a half-life of approximately 5 to 6 hours in healthy adults, meaning a 200 mg caffeine dose at 2:00 PM leaves roughly 100 mg of stimulant activity at 7:00 PM. Individual variation in CYP1A2 activity makes some patients substantially more sensitive; slow metabolizers may experience insomnia from morning coffee.